Cargando…
Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425848/ https://www.ncbi.nlm.nih.gov/pubmed/28536694 http://dx.doi.org/10.1155/2017/2917925 |
_version_ | 1783235361469628416 |
---|---|
author | Yoon, Won Sup Yang, Dae Sik Lee, Jung Ae Lee, Nam Kwon Park, Young Je Kim, Chul Yong Lee, Nak Woo Hong, Jin Hwa Lee, Jae Kwan Song, Jae Yun |
author_facet | Yoon, Won Sup Yang, Dae Sik Lee, Jung Ae Lee, Nam Kwon Park, Young Je Kim, Chul Yong Lee, Nak Woo Hong, Jin Hwa Lee, Jae Kwan Song, Jae Yun |
author_sort | Yoon, Won Sup |
collection | PubMed |
description | Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection (PLND). This study aimed to validate these models using our cohort with adjuvant radiotherapy. Methods. According to the eligibility criteria of nomogram studies, patients were enrolled in Group A (N = 109) for the two KROG models (RH with PLND and whole pelvic irradiation) and Group B (N = 101) for the SNUH/AMC model (RH with PLND and squamous histology). Using Cox-regression hazard models, the prognostic factors of our cohorts were evaluated. The risk probabilities induced from published nomogram scores were calculated and the concordance indices were evaluated. Results. Group A had 88.1% 5-year OS and 86.0% 5-year DMFS. Group B had 83.0% 5-year DFS. In multivariate analyses, large tumor size for OS (HR 8.62, P < 0.001) and DMFS (HR 5.13, P = 0.003), young age (≤40 versus 41–64 years) for OS (HR 4.63, P = 0.097) and DFS (HR 3.44, P = 0.051), and multiple lymph node metastases (0 versus ≥3) for DMFS (HR 4.03, P = 0.031) and DFS (HR 3.90, P = 0.038) were significantly correlated. The concordance indices for OS, DMFS, and DFS were 0.612 (P = 0.002), 0.597 (P = 0.014), and 0.587 (P = 0.020), respectively. Conclusion. The developed nomogram models after RH and PLND are clinically useful in predicting various types of survival with significance. |
format | Online Article Text |
id | pubmed-5425848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-54258482017-05-23 Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors Yoon, Won Sup Yang, Dae Sik Lee, Jung Ae Lee, Nam Kwon Park, Young Je Kim, Chul Yong Lee, Nak Woo Hong, Jin Hwa Lee, Jae Kwan Song, Jae Yun Biomed Res Int Clinical Study Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival [DFS], and KROG 12-08 for distant metastases-free survival [DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection (PLND). This study aimed to validate these models using our cohort with adjuvant radiotherapy. Methods. According to the eligibility criteria of nomogram studies, patients were enrolled in Group A (N = 109) for the two KROG models (RH with PLND and whole pelvic irradiation) and Group B (N = 101) for the SNUH/AMC model (RH with PLND and squamous histology). Using Cox-regression hazard models, the prognostic factors of our cohorts were evaluated. The risk probabilities induced from published nomogram scores were calculated and the concordance indices were evaluated. Results. Group A had 88.1% 5-year OS and 86.0% 5-year DMFS. Group B had 83.0% 5-year DFS. In multivariate analyses, large tumor size for OS (HR 8.62, P < 0.001) and DMFS (HR 5.13, P = 0.003), young age (≤40 versus 41–64 years) for OS (HR 4.63, P = 0.097) and DFS (HR 3.44, P = 0.051), and multiple lymph node metastases (0 versus ≥3) for DMFS (HR 4.03, P = 0.031) and DFS (HR 3.90, P = 0.038) were significantly correlated. The concordance indices for OS, DMFS, and DFS were 0.612 (P = 0.002), 0.597 (P = 0.014), and 0.587 (P = 0.020), respectively. Conclusion. The developed nomogram models after RH and PLND are clinically useful in predicting various types of survival with significance. Hindawi 2017 2017-04-27 /pmc/articles/PMC5425848/ /pubmed/28536694 http://dx.doi.org/10.1155/2017/2917925 Text en Copyright © 2017 Won Sup Yoon et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Yoon, Won Sup Yang, Dae Sik Lee, Jung Ae Lee, Nam Kwon Park, Young Je Kim, Chul Yong Lee, Nak Woo Hong, Jin Hwa Lee, Jae Kwan Song, Jae Yun Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title_full | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title_fullStr | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title_full_unstemmed | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title_short | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors |
title_sort | validation of nomograms for survival and metastases after hysterectomy and adjuvant therapy in uterine cervical cancer with risk factors |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425848/ https://www.ncbi.nlm.nih.gov/pubmed/28536694 http://dx.doi.org/10.1155/2017/2917925 |
work_keys_str_mv | AT yoonwonsup validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT yangdaesik validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT leejungae validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT leenamkwon validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT parkyoungje validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT kimchulyong validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT leenakwoo validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT hongjinhwa validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT leejaekwan validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors AT songjaeyun validationofnomogramsforsurvivalandmetastasesafterhysterectomyandadjuvanttherapyinuterinecervicalcancerwithriskfactors |